门诊与住院使用合成渗透性扩张器进行引产前宫颈成熟的比较:一项随机临床试验
这项随机临床试验纳入339名足月、宫颈条件不佳且无需住院监护的引产孕妇,比较门诊与住院使用合成渗透性扩张器进行宫颈成熟对住院时间的影响。门诊组住院超过48小时的比例为53%,低于住院组的89%(RR 0.60,95%CI 0.52-0.70),且门诊组总住院时间更短、入院至活跃产程时间更短、24小时内阴道分娩更常见、成熟期间使用镇痛药更少,两组分娩方式及母婴结局无显著差异。
要点
- 门诊组住院超过48小时的比例为53%(89/167),住院组为89%(152/171),RR 0.60(95%CI 0.52-0.70)。
- 门诊组总住院时间及入院至活跃产程时间均短于住院组。
- 门诊组24小时内阴道分娩更常见,成熟期间使用镇痛药更少,两组分娩方式及母婴结局无显著差异。
核心结论
- 门诊使用宫颈渗透性扩张器进行宫颈成熟较住院成熟缩短了住院时间,且未出现显著不良结局。
研究设计与样本
- 随机临床试验,纳入足月、宫颈条件不佳(扩张小于3厘米且消退小于60%)且无需住院母婴监护的引产孕妇,计划引产当日置入合成渗透性扩张器棒。
- 2018年11月至2021年11月共随机339名参与者(住院组171名,门诊组167名,1名退出)。
- 门诊组在胎心监护 reassuring 后于置入12小时后返回或必要时提前返回,住院组留在医院;第一轮成熟后后续处理由临床医护人员决定。
- 主要结局为住院时间超过48小时的参与者比例;样本量338预计提供85%把握度检测组间30%差异。
主要发现
- 门诊组住院超过48小时的比例为53%(89/167),住院组为89%(152/171),RR 0.60(95%CI 0.52-0.70)。
- 门诊组总住院时间及入院至活跃产程时间均短于住院组。
- 门诊组24小时内阴道分娩更常见,成熟期间使用镇痛药更少。
- 两组分娩方式及其他母婴结局无显著差异。
- 门诊组4名因疑似临产和胎膜破裂在12小时前入院,住院组19名在12小时前取出装置。
关键数值与推荐
- 宫颈条件不佳定义为扩张小于3厘米且消退小于60%。
- 主要结局为住院时间超过48小时的比例,门诊组53%(89/167) vs 住院组89%(152/171),RR 0.60(95%CI 0.52-0.70)。
临床怎么用
- 对于足月、宫颈条件不佳且无需住院母婴监护的引产孕妇,门诊使用合成渗透性扩张器进行宫颈成熟可缩短住院时间,且未增加显著不良结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether outpatient cervical ripening with a synthetic osmotic dilator shortens the length of hospital stay in term pregnancies undergoing labor induction. METHODS: Pregnant participants scheduled for labor induction at term with unfavorable cervix (less than 3-cm dilated and less than 60% effaced) and not requiring inpatient maternal or fetal monitoring were consented, and synthetic osmotic dilator rods were inserted on the day of scheduled induction. After reassuring fetal heart tracing, patients randomized to the outpatient group were asked to return 12 hours after insertion or sooner if needed. Those randomized to the inpatient group remained in the hospital. After the first round of ripening, additional ripening, oxytocin, and labor management were left up to the clinical health care professionals. The primary outcome was the proportion of participants with hospital stays longer than 48 hours. We estimated that a sample size of 338 would provide 85% power to detect a 30% difference between groups. RESULTS: From November 2018 to November 2021, 339 participants were randomized (171 inpatient, 167 outpatient, one withdrawal). Four patients in the outpatient group were admitted before12 hours for suspected labor and rupture of membranes, and 19 in the inpatient group had the device removed before 12 hours. The proportion of participants with hospital stays longer than 48 hours was lower in the outpatient group compared with the inpatient group (89 [53%] vs 152 [89%], relative risk [RR] 0.60, 95% CI 0.52-0.70). Patients in the outpatient group had a shorter total length of stay and time from admission to active labor. They were more likely to have a vaginal delivery within 24 hours of admission and were less likely to receive analgesics during ripening. Route of delivery and other maternal and neonatal outcomes were not significantly different between groups. CONCLUSION: Outpatient cervical ripening with a cervical osmotic dilator decreased hospital stay compared with inpatient ripening, without significant adverse outcomes. FUNDING SOURCE: Medicem Technology s.r.o., Czech Republic. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03665688.
引用
- Saad AF, Gavara R, Senguttuvan RN, et al. Outpatient Compared With Inpatient Preinduction Cervical Ripening Using a Synthetic Osmotic Dilator: A Randomized Clinical Trial. Obstet Gynecol. 2022. PMID: 36083097. doi:10.1097/AOG.0000000000004942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。